Skip to main content
Erschienen in: Journal of Clinical Immunology 1/2007

01.01.2007 | Original Paper

The Effect of Natural Killer Cell Killer Ig-Like Receptor Alloreactivity on the Outcome of Bone Marrow Stem Cell Transplantation for Severe Combined Immunodeficiency (SCID)

verfasst von: M. D. KELLER, D.-F. CHEN, S. A. CONDRON, N. LIU, N. L. REINSMOEN, R. H. BUCKLEY

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Natural killer (NK) cell alloreactions against recipient cells in the setting of bone marrow transplantation have been associated with decreased rates of graft-versus-host disease (GVHD) and improved survival in transplant recipients with myeloid leukemia. These alloreactions are predicted by the absence of recipient HLA class I ligands for donor inhibitory killer Ig-like receptors (KIR). We hypothesized that donor NK cell alloreactions against recipient cells may affect the development of T and B-cell functions and incidence of GVHD in infants with severe combined immunodeficiency (SCID). Of the 156 patients with SCID who had received related bone marrow transplants without pretransplant chemotherapy or posttransplant GVHD prophylaxis, 137 patient–donor pairs were evaluated for the absence of recipient HLA class I ligands for donor inhibitory KIR. Analysis showed that the absence of a KIR ligand had no effect on the incidence or severity of GVHD (R 2 = 0.95, p = 0.84), development of T-cell function (R 2 = 1.05, p = 0.69), production of IgA (p = 0.46) or IgM (p = 0.33), or on 5-year survival (R 2 = 1.21, p = 0.10). Further, in patients possessing native NK cells, the absence of KIR ligands in donors for recipient-inhibitory KIR did not alter transplantation outcomes. This study suggests that inhibitory KIR/HLA interactions do not play a significant role in bone marrow transplantation for SCID.
Literatur
1.
Zurück zum Zitat Buckley RH: Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22:625–655, 2004 PubMedCrossRef Buckley RH: Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 22:625–655, 2004 PubMedCrossRef
2.
Zurück zum Zitat Ryser O, Morell A, Hitzig W: Primary immunodeficiencies in Switzerland: First report of the national registry in adults and children. J Clin Immunol 8:479–488, 1988 PubMedCrossRef Ryser O, Morell A, Hitzig W: Primary immunodeficiencies in Switzerland: First report of the national registry in adults and children. J Clin Immunol 8:479–488, 1988 PubMedCrossRef
3.
Zurück zum Zitat Myers L, Patel DD, Buck JM, Buckley RH: Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872–878, 2002 PubMedCrossRef Myers L, Patel DD, Buck JM, Buckley RH: Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872–878, 2002 PubMedCrossRef
4.
Zurück zum Zitat Buckley RH, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts JL, Myers LA, Ward FE: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340(7):508–516, 1999 PubMedCrossRef Buckley RH, Schiff SE, Schiff RI, Markert ML, Williams LW, Roberts JL, Myers LA, Ward FE: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340(7):508–516, 1999 PubMedCrossRef
5.
Zurück zum Zitat Barao I, Murphy WJ: The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant 9(12):727–741, 2003 PubMedCrossRef Barao I, Murphy WJ: The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant 9(12):727–741, 2003 PubMedCrossRef
6.
Zurück zum Zitat Farag S, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 100:1935–1947, 2002 PubMedCrossRef Farag S, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 100:1935–1947, 2002 PubMedCrossRef
7.
Zurück zum Zitat Parham P, McQueen K: Alloreactive killer cells: Hindrance and help for haematopoietic transplants. Nat Rev Immunol 3(2):108–122, 2003 PubMedCrossRef Parham P, McQueen K: Alloreactive killer cells: Hindrance and help for haematopoietic transplants. Nat Rev Immunol 3(2):108–122, 2003 PubMedCrossRef
8.
Zurück zum Zitat Raulet D, Vance R, McMahon C: Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291–330, 2001 PubMedCrossRef Raulet D, Vance R, McMahon C: Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19:291–330, 2001 PubMedCrossRef
10.
Zurück zum Zitat Gumperz J, Litwin V, Phillips JH, Lanier LL, Parham P: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181(3):1133–1144, 1995 PubMedCrossRef Gumperz J, Litwin V, Phillips JH, Lanier LL, Parham P: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181(3):1133–1144, 1995 PubMedCrossRef
11.
Zurück zum Zitat Parham P: MHC class I molecules and KIRs in human history, health, and survival. Nat Rev Immunol 5:201–214, 2005 PubMedCrossRef Parham P: MHC class I molecules and KIRs in human history, health, and survival. Nat Rev Immunol 5:201–214, 2005 PubMedCrossRef
12.
13.
Zurück zum Zitat Orange JS: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 4(15):1545–1558, 2002 PubMedCrossRef Orange JS: Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 4(15):1545–1558, 2002 PubMedCrossRef
14.
Zurück zum Zitat Murphy WJ, Bennett M, Kumar V, Longo DL: Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 148(9):2953–2960, 1992 PubMed Murphy WJ, Bennett M, Kumar V, Longo DL: Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J Immunol 148(9):2953–2960, 1992 PubMed
15.
Zurück zum Zitat Gaines AD, Schiff S, Buckley RH: Donor type natural killer cells after haploidentical T-cell depleted bone marrow stem cell transplantation in a patient with adenosine deaminase-deficient severe combined immunodeficiency. Clin Immunol Immunopathol 60(2):299–304, 1991 PubMedCrossRef Gaines AD, Schiff S, Buckley RH: Donor type natural killer cells after haploidentical T-cell depleted bone marrow stem cell transplantation in a patient with adenosine deaminase-deficient severe combined immunodeficiency. Clin Immunol Immunopathol 60(2):299–304, 1991 PubMedCrossRef
16.
Zurück zum Zitat Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS: KIR reconstitution is altered by T-cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106(13):4370–4376, 2005 PubMedCrossRef Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS: KIR reconstitution is altered by T-cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106(13):4370–4376, 2005 PubMedCrossRef
17.
Zurück zum Zitat Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172(1):644–650, 2004 PubMed Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172(1):644–650, 2004 PubMed
18.
Zurück zum Zitat Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P: Roles for HLA and KIR polymorphisms in natural killer cell repetoire selection and modulation of effector function. J Exp Med 203(3):633–645, 2006 PubMedCrossRef Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P: Roles for HLA and KIR polymorphisms in natural killer cell repetoire selection and modulation of effector function. J Exp Med 203(3):633–645, 2006 PubMedCrossRef
19.
Zurück zum Zitat Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin R, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94(1):333–339, 1995 Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin R, Martelli MF, Velardi A: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94(1):333–339, 1995
20.
Zurück zum Zitat Ruggeri L, Capanni M, Urbani E, Perruccio K, Schlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni, F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoeitic transplants. Science 295(5562):2097–2100, 2002 PubMedCrossRef Ruggeri L, Capanni M, Urbani E, Perruccio K, Schlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni, F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoeitic transplants. Science 295(5562):2097–2100, 2002 PubMedCrossRef
21.
Zurück zum Zitat Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103(7):2860–2861, 2004 PubMedCrossRef Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103(7):2860–2861, 2004 PubMedCrossRef
22.
Zurück zum Zitat Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 100(10):3825–3827, 2002 PubMedCrossRef Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 100(10):3825–3827, 2002 PubMedCrossRef
23.
Zurück zum Zitat Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102(3):814–819, 2003 PubMedCrossRef Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102(3):814–819, 2003 PubMedCrossRef
24.
Zurück zum Zitat Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105(12):4878–4884, 2005 PubMedCrossRef Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105(12):4878–4884, 2005 PubMedCrossRef
25.
Zurück zum Zitat Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. I. Graft rejection by heavily irradiated “responder” mice. J Exp Med 134(1):83–102, 1971 PubMedCrossRef Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. I. Graft rejection by heavily irradiated “responder” mice. J Exp Med 134(1):83–102, 1971 PubMedCrossRef
26.
Zurück zum Zitat Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by F1 hybrid mice. J Exp Med 134(6):1513–1528, 1971 PubMedCrossRef Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by F1 hybrid mice. J Exp Med 134(6):1513–1528, 1971 PubMedCrossRef
27.
Zurück zum Zitat Murphy WJ, Kumar V, Bennett M: Rejection of bone marrow allograft by mice with severe combined immunodeficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 165(4):1212–1217, 1987 PubMedCrossRef Murphy WJ, Kumar V, Bennett M: Rejection of bone marrow allograft by mice with severe combined immunodeficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 165(4):1212–1217, 1987 PubMedCrossRef
28.
Zurück zum Zitat O’Reilly RJ, Brochstein J, Collins N, Keever C, Kapoor N, Kirkpatrick D, Kernan N, Dupont B, Burns J, Reisner Y: Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sang 51:81–86, 1986 PubMed O’Reilly RJ, Brochstein J, Collins N, Keever C, Kapoor N, Kirkpatrick D, Kernan N, Dupont B, Burns J, Reisner Y: Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sang 51:81–86, 1986 PubMed
29.
Zurück zum Zitat Dal-Cortivo L, Ouachee-Chardin M, Hirsch I, Blanche S, Fischer A, Cavazzana-Calvo M, Caillat-Zucman S: Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity? Bone Marrow Transplant 34(11):945–947, 2004 PubMedCrossRef Dal-Cortivo L, Ouachee-Chardin M, Hirsch I, Blanche S, Fischer A, Cavazzana-Calvo M, Caillat-Zucman S: Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity? Bone Marrow Transplant 34(11):945–947, 2004 PubMedCrossRef
30.
Zurück zum Zitat Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). N Engl J Med 316(10):589–596, 1987 PubMedCrossRef Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). N Engl J Med 316(10):589–596, 1987 PubMedCrossRef
31.
Zurück zum Zitat Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C: Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8(5):423–425, 2002 PubMedCrossRef Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C: Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8(5):423–425, 2002 PubMedCrossRef
32.
Zurück zum Zitat Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18(4):295–304, 1974 PubMedCrossRef Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18(4):295–304, 1974 PubMedCrossRef
33.
Zurück zum Zitat Iwasaki T: Recent advances in the treatment of graft-versus-host disease. Clin Med Res 2(4):243–252, 2004 PubMedCrossRef Iwasaki T: Recent advances in the treatment of graft-versus-host disease. Clin Med Res 2(4):243–252, 2004 PubMedCrossRef
34.
Zurück zum Zitat Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101(9):1936–1946, 2004 PubMedCrossRef Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101(9):1936–1946, 2004 PubMedCrossRef
35.
Zurück zum Zitat Cooper M, Fehniger T, Caligiuri M. The biology of human natural killer cell subsets. Trends Immunol 22(11):633–640, 2001 PubMedCrossRef Cooper M, Fehniger T, Caligiuri M. The biology of human natural killer cell subsets. Trends Immunol 22(11):633–640, 2001 PubMedCrossRef
36.
Zurück zum Zitat Blanca IR, Bere EW, Young HA, Ortaldo JR: Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: Role of memory B cells and CD5+ B cells. J Immunol 167(11):6132–6139, 2001 PubMed Blanca IR, Bere EW, Young HA, Ortaldo JR: Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: Role of memory B cells and CD5+ B cells. J Immunol 167(11):6132–6139, 2001 PubMed
37.
Metadaten
Titel
The Effect of Natural Killer Cell Killer Ig-Like Receptor Alloreactivity on the Outcome of Bone Marrow Stem Cell Transplantation for Severe Combined Immunodeficiency (SCID)
verfasst von
M. D. KELLER
D.-F. CHEN
S. A. CONDRON
N. LIU
N. L. REINSMOEN
R. H. BUCKLEY
Publikationsdatum
01.01.2007
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 1/2007
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-006-9058-7

Weitere Artikel der Ausgabe 1/2007

Journal of Clinical Immunology 1/2007 Zur Ausgabe

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.